Okyo Pharma awards chief scientific officer 5M options

Nov. 24, 2022 5:37 AM ETOKYO Pharma Limited (OKYO), EMMLFBy: Ravikash, SA News Editor

Shot of a businessman and businesswoman shaking hands in a modern office

Delmaine Donson

  • Okyo Pharma (NASDAQ:OKYO) (OTCPK:EMMLF) said its board awarded the company's Chief Scientific Officer Raj Patil 5M options at an exercise price of 6.25 pence per share.
  • The London-based company added that the award was granted in recognition of Patil's work in achieving an investigational new drug (IND) application filing with the U.S. Food and Drug Administration (FDA) seeking clearance to start a trial of OK-101 to treat dry eye disease.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.